Business Description
Telomir Pharmaceuticals Inc
NAICS : 541713
SIC : 2834
ISIN : US87975F1049
Total Employee Number:
5Description
Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.86 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -124.7 | |||||
3-Year EPS without NRI Growth Rate | -124.9 | |||||
3-Year FCF Growth Rate | -94.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.09 | |||||
9-Day RSI | 44.58 | |||||
14-Day RSI | 46.42 | |||||
3-1 Month Momentum % | -3.76 | |||||
6-1 Month Momentum % | -9.86 | |||||
12-1 Month Momentum % | 9.4 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7 | |||||
Quick Ratio | 7 | |||||
Cash Ratio | 6.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.1 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -253.77 | |||||
ROA % | -211.04 | |||||
ROCE % | -253.74 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 8.86 | |||||
Price-to-Tangible-Book | 8.86 | |||||
EV-to-EBIT | -8.64 | |||||
EV-to-EBITDA | -8.64 | |||||
EV-to-Forward-Revenue | 28.69 | |||||
EV-to-FCF | -17.34 | |||||
| Price-to-Net-Current-Asset-Value | 8.86 | |||||
| Price-to-Net-Cash | 8.86 | |||||
Earnings Yield (Greenblatt) % | -11.57 | |||||
FCF Yield % | -5.39 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TELO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Telomir Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.29 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 67.01 | ||
| 14-Day RSI | 46.42 | ||
| 14-Day ATR ($) | 0.065622 | ||
| 20-Day SMA ($) | 1.2645 | ||
| 12-1 Month Momentum % | 9.4 | ||
| 52-Week Range ($) | 1.05 - 3.1 | ||
| Shares Outstanding (Mil) | 68.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Telomir Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Telomir Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 124 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 36 days | ||
| First quarter earnings results for 2026 | 2026-05-14 | 1.23 (-5.38%) | ||
| General meeting for 2025 | 2026-03-23 10:00 | 1.32 (+2.33%) | ||
| Annual report for 2025 | 2026-03-17 | 1.34 (+2.29%) | ||
| General meeting for 2024 | 2025-12-30 10:00 | 1.33 (-6.99%) | ||
| Third quarter earnings results for 2025 | 2025-11-10 | 1.31 (-1.50%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 1.60 (+4.58%) | ||
| First quarter earnings results for 2025 | 2025-05-14 | 2.75 (+5.77%) | ||
| Annual report for 2024 | 2025-02-04 | 4.17 (-14.02%) |
Show
Entries
Telomir Pharmaceuticals Inc Frequently Asked Questions
What is Telomir Pharmaceuticals Inc(TELO)'s stock price today?
The current price of TELO is $1.24. The 52 week high of TELO is $3.10 and 52 week low is $1.05.
When is next earnings date of Telomir Pharmaceuticals Inc(TELO)?
The next earnings date of Telomir Pharmaceuticals Inc(TELO) is 2026-08-14 Est..
Does Telomir Pharmaceuticals Inc(TELO) pay dividends? If so, how much?
Telomir Pharmaceuticals Inc(TELO) does not pay dividend.
Guru Commentaries on NAS:TELO
No articles.
Press Release
Articles on Telomir Pharmaceuticals Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers